Mubadala Investment Company

Mubadala Investment Company is the Abu Dhabi sovereign wealth investor, with a New York office among its global presence, deploying long-duration capital into life sciences, pharmaceuticals, and broader healthcare infrastructure. Within healthcare it focuses on Pharma and Therapeutics and Life Sciences Tools, sub-sectors that align with its appetite for capital-intensive, R&D-heavy bets. AI is not flagged as a dedicated thesis.

Mubadala writes growth-stage checks of $25M and up, and as a sovereign investor its actual single-deal exposure can run far larger when warranted. The firm is global, investing across the US, Europe, the Middle East, and Asia. Specific named portfolio companies and team members are not detailed in the record provided here; Mubadala’s investor relations site is the best authoritative source.

For founders, Mubadala is a relevant conversation only at meaningful scale. The realistic profile is later-stage biotech, life sciences tools companies with commercial traction, pharma manufacturing platforms, or healthcare infrastructure deals. Early-stage AI founders, even those with a life sciences angle, will not match the firm’s check size or hold profile. When the company is large enough, the appeal is patient capital and access to the broader Mubadala portfolio across geographies.